24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

A crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour IOP control and safety of travoprost/timolol fixed combination given once in the evening, versus that of latanoprost/timolol fixed combination given once in the evening in patients with exfoliative glaucoma. The primary objective of this trial is to compare the quality of 24-hour IOP control after 3 months of chronic therapy with these two medications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Aristotle University Of Thessaloniki
• Collaborator: Alcon Research
• Treatments: Latanoprost; Timolol; Travoprost

Criteria

Inclusion Criteria:

• Patient has XFG and is older than 29 years

• The IOP without treatment is greater than 25 mm Hg and lower than 40 mm Hg at baseline (2 readings at 10:00)

• Patient can be safely washed out without risk for significant deterioration

• Distance best corrected Snelen visual acuity better than 0.1

• No contraindication to prostaglandins or β-blockers

• No history of lack of response (<10% reduction) to any medication

• Patient can understand the instructions and comply to medications

• Open normal appearing angles

• No sign of ocular infection, except blepharitis, corneal abnormality that may affect IOP measurements etc

Exclusion Criteria:

• History of trauma, inflammation, surgery, past use of steroids (within 2 months), severe dry eyes and use of contact lenses

• Patient is a female of childbearing potential or lactating mother